S Madsbad, T Krarup, CF Deacon, JJ Holst - Current Opinion in Clinical Nutrition & Metabolic Care, 2008 - journals.lww.com Recent findings: The injectable glucagon-like peptide-1 receptor agonists
exenatide significantly improves glycaemic control, with average reductions in
haemoglobin A1c of about 1.0%, fasting plasma glucose of about 1.4 mmol/l, ... Cited by 24 - Related articles - All 2 versions
SE Inzucchi, DK McGuire - Circulation, 2008 - Am Heart Assoc This is the second of a 2-part series focusing on newer therapies for type 2
diabetes and their cardiovascular implications. In the first segment, we
reviewed the thiazolidinediones, highlighting emerging data concerning ... Cited by 22 - Related articles - All 6 versions
- ►eje-online.org LF Van Gaal, SW Gutkin, MA Nauck - European journal of endocrinology, 2008 - EFES Type 2 diabetes mellitus is associated with progressive decreases in pancreatic
β-cell function. Most patients thus require increasingly intensive treatment,
including oral combination therapies followed by insulin. Fear of ... Cited by 10 - Related articles - BL Direct - All 11 versions
CA Sheffield, MP Kane, RS Busch, G Bakst, … - Endocrine Practice, 2008 - AACE Diabetes mellitus affects approximately 21 million Americans, including 90% to
95% with type 2 diabetes mellitus (T2DM) (1). Inadequately controlled diabetes
is associated with increased morbidity due to microvascular and ... Cited by 6 - Related articles - BL Direct - All 2 versions
N Mikhail - Expert Opin. Investig. Drugs, 2008 - informahealthcare.com Background: Exenatide is an incretin mimetic, while sitagliptin and vildagliptin
are incretin enhancers used as adjunctive therapy in patients with type 2
diabetes failing oral agents. Sitagliptin and vildagliptin can also be used ... Cited by 4 - Related articles - BL Direct - All 9 versions
DM Kendall, RM Cuddihy, RM Bergenstal - European Journal of Internal Medicine, 2009 - Elsevier Incretin-based therapies address the progressive nature of type 2 diabetes
mellitus, not only by addressing glucose control but also with weight-neutral
(ie, dipeptidyl peptidase–4 inhibitors sitagliptin and vildagliptin) and ... Cited by 4 - Related articles - All 38 versions
- Free from Publisher J Rosenstock, V Fonseca - Diabetes Care, 2007 - Am Diabetes Assoc The recent American Diabetes Association/European Association for the Study of
Diabetes consensus treatment algorithm for type 2 diabetes has advanced basal
insulin treatment as a much earlier therapeutic option following a ... Cited by 3 - Related articles - All 6 versions
S Matthaei, R Bierwirth, A Fritsche, B … - Update der Evidenzbasierten Leitlinie der Deutschen …, 2008 - thieme-connect.com Der Diabetes mellitus Typ 2 ist eine chronisch progrediente Erkrankung, die
durch vererbte und erworbene Insulinresistenz und Insulinsekretionsstörung
charakterisiert ist. Um die bei Typ-2-Diabetikern deutlich erhöhte ... Cited by 4 - Related articles
MJ Fowler - Clinical Diabetes, 2008 - Am Diabetes Assoc Insulin is the oldest and the most effective treatment to control glucose levels
in diabetic patients. It was first used in the treatment of diabetes by
Frederick Banting and Charles Best in 1922. Although originally thought to ... Cited by 2 - Related articles - BL Direct - All 2 versions
